Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Gap Up – Here’s Why
by Amy Steele · The Cerbat GemSanten Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $10.0250, but opened at $10.48. Santen Pharmaceutical shares last traded at $10.78, with a volume of 2,504 shares traded.
Wall Street Analyst Weigh In
Separately, Zacks Research upgraded Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company has an average rating of “Hold”.
Check Out Our Latest Analysis on Santen Pharmaceutical
Santen Pharmaceutical Stock Performance
The firm has a 50 day simple moving average of $10.93 and a two-hundred day simple moving average of $10.67. The firm has a market capitalization of $3.39 billion and a P/E ratio of 0.10.
Santen Pharmaceutical Company Profile
Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.
With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.